BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS

S. Soverini, M. Martelli, L. Bavaro, C. De Benedittis, S. Sica, F. Sorà, A. Iurlo, M. Bonifacio, P. Pregno, S. Galimberti, F. Lunghi, F. Albano, M. D’Adda, M. Crugnola, I. Capodanno, F. Castagnetti, G. Gugliotta, C. Papayannidis, G. Rosti, A. PercesepeF. Mignone, M. Baccarani, G. Martinelli, M. Cavo

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)2102-2107
Number of pages6
Issue number7
Publication statusPublished - 2021


  • BCR ABL protein
  • BCR-ABL1 fusion protein, human
  • protein kinase inhibitor
  • protein tyrosine kinase
  • drug effect
  • drug resistance
  • genetics
  • high throughput sequencing
  • human
  • leukemia
  • Philadelphia 1 chromosome
  • prevalence
  • procedures
  • Drug Resistance, Neoplasm
  • Fusion Proteins, bcr-abl
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Leukemia
  • Philadelphia Chromosome
  • Prevalence
  • Protein Kinase Inhibitors
  • Protein-Tyrosine Kinases

Cite this